Relmacabtagene Autoleucel
Phase 3Cell therapy
Relmacabtagene Autoleucel is one of 60 biologic programs targeting Aggressive B-cell NHL. It is currently in Phase 3.
3
Indications
7
Total Trials
5
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Relmacabtagene Autoleucel
SShanghai Ming Ju Biotechnology Co., Ltd.
Phase 3
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma3 trials
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Not yet recruiting·—·Phase 4·NCT05814848·13 enrolled
Aggressive B-cell NHL1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Relmacabtagene Autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details